News
BRRGF
1.770
NaN%
--
Oncoinvent Asa Earnings Call Highlights Trial Momentum
TipRanks · 08/30 00:25
Oncoinvent advances Radspherin trials and IP as losses widen in first half 2026
TipRanks · 08/27 05:46
Oncoinvent Sets August Webcast as Radspherin Advances Toward Post-Surgical Cancer Standard
TipRanks · 08/17 05:38
Oncoinvent’s Radspherin Shows Favorable Dosimetry in Phase 1 Cancer Studies
TipRanks · 08/11 05:40
Oncoinvent Aligns Board Incentives with Equity Grants as Radspherin Advances
TipRanks · 05/20 19:02
Oncoinvent Clears AGM Agenda as It Pushes Radspherin Toward Post-Surgical Cancer Market
TipRanks · 05/20 09:35
Oncoinvent Finalizes Major Share Capital Reduction Amid Progress on Cancer Therapy Radspherin
TipRanks · 05/05 08:33
Oncoinvent Advances Radspherin Program With New Patent, Phase 2 Recruitment and CFO Hire
TipRanks · 04/29 05:40
Oncoinvent Sets Virtual AGM as Radspherin Development Advances
TipRanks · 04/28 11:10
Oncoinvent Sets April Webcast as Radspherin Program Gains Momentum
TipRanks · 04/23 05:37
Oncoinvent Publishes 2025 Annual Report as Radspherin Program Advances
TipRanks · 04/22 15:07
Oncoinvent Secures Key Chinese Patent for Lead Radiopharmaceutical Radspherin
TipRanks · 03/19 07:33
Oncoinvent Grants CEO New Share Options as It Advances Radiopharmaceutical Pipeline
TipRanks · 03/11 22:08
Oncoinvent Posts Strong 2H 2025 as Radspherin Data and Oslo Uplisting Bolster Growth Plans
TipRanks · 02/26 08:45
Oncoinvent’s Radspherin Shows Durable Ovarian Cancer Control in Phase 1 Study
TipRanks · 02/17 07:03
Oncoinvent Sets Out 2025–2026 Financial Reporting Calendar and Quarterly Market Updates
TipRanks · 02/03 10:04
Oncoinvent Expands Phase 2 Radspherin Trial with New Sites and First Patient Enrollment
TipRanks · 01/29 07:48
Oncoinvent Advances Radspherin® Phase 2 Trial in Advanced Ovarian Cancer: What Investors Should Watch
TipRanks · 01/23 16:34
Oncoinvent Registers Share Capital Increase Ahead of Reverse Share Split
TipRanks · 01/15 09:35
Oncoinvent Launches 100-for-1 Reverse Share Split and New ISIN on Oslo Bourse
TipRanks · 01/14 15:02
More
Webull provides a variety of real-time BRRGF stock news. You can receive the latest news about Oncoinvent ASA through multiple platforms. This information may help you make smarter investment decisions.
About BRRGF
Oncoinvent ASA, formerly Bergenbio ASA, is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. The Company is based in Bergen, Norway with a subsidiary in Oxford, UK.